MorphoSys AG (XSWX:MOR) Accounts Receivable : CHF30.3 Mil (As of Dec. 2023)

View and export this data going back to 1999. Start your Free Trial

What is MorphoSys AG Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. MorphoSys AG's accounts receivables for the quarter that ended in Dec. 2023 was CHF30.3 Mil.

Accounts receivable can be measured by Days Sales Outstanding. MorphoSys AG's Days Sales Outstanding for the quarter that ended in Dec. 2023 was 49.57.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. MorphoSys AG's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was CHF-34.22.

MorphoSys AG Accounts Receivable Historical Data

The historical data trend for MorphoSys AG's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MorphoSys AG Accounts Receivable Chart

MorphoSys AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Receivable

Get a 7-Day Free Trial

16.47

90.09

79.00

90.03

30.27

MorphoSys AG Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Accounts Receivable	Get a 7-Day Free Trial															90.03	62.35	69.52	-	30.27

MorphoSys AG Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

MorphoSys AG Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

MorphoSys AG's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	30.267	/	55.715	*	91
=	49.57

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), MorphoSys AG's accounts receivable are only considered to be worth 75% of book value:

MorphoSys AG's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(643.89	+	0.75 * 30.267	+	0.5 * 58.535	-	1864.707
-	0	-	0)	/	34.1607
=	-34.22

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

MorphoSys AG Accounts Receivable Related Terms

Thank you for viewing the detailed overview of MorphoSys AG's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

MorphoSys AG (XSWX:MOR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MorphoSys AG (XSWX:MOR) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

MPSYF:USA MOR:USA 1MOR:Italy MORd:UK 0NDV:UK MOR:Germany MOR:Austria

Address

Semmelweisstrasse 7, Planegg, BY, DEU, 82152

Website

https://www.morphosys.com

MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.